The headline result was a mean 17.5% body-weight reduction at 24 weeks in the 12 mg arm, with clear dose-response behavior across the four active doses
GLP-1 meds can lead to muscle loss, not just fat loss
A systematic review ScienceDirect science/article/pii/S2214623724000048 [64] What is the pipeline for future medications for obesity
Research has demonstrated that GLP-1RAs significantly inhibit the expression of MMP-2 and MMP-9 in the human ovarian cancer cell line SKOV-3 within a TNF--induced inflammatory microenvironment, while simultaneously upregulating the levels of their inhibitors, tissue inhibitors-1 (TIMP-1) and tissue inhibitors-2 (TIMP-2) [78, 87]
Current batch COAs are posted publicly on our Certifications page for independent verification
The American Journal of Clinical Nutrition , 87(1), 155S158S